Biosimilar Manufacturing solution center
-
High-Titer rAAV Production In Bioreactors Using Producer Cell Lines
3/6/2024
Here, we detail the upstream process development and optimization for an AAV8-GFP proof-of-concept (PoC) producer single cell clone (SCC) in both batch and perfusion modes.
-
Safer AAV Through Reduced Host-Cell DNA Encapsidation
3/6/2024
While most hcDNA molecules outside AAV particles can be eliminated during downstream processing, encapsidated hcDNA molecules remain largely undetectable. Learn how to overcome this critical issue.
-
Cost Modeling Comparison Of Bioreactors To Produce Adherent Cell Products
3/6/2024
This study employs BioSolve software, a reference for cost analyses in the biopharmaceutical industry, to compare the upstream manufacturing costs between multitray stacks and the iCELLis™ bioreactor.
-
Shocking! Biotech Facilities Don't Maintain Themselves
3/4/2024
Don't get trapped in the misconception that only core process systems need maintenance. Here are some real-life examples of facility maintenance programs gone wrong.
-
Demand More From Your Oligo Synthesizer
3/4/2024
The market for oligonucleotide therapeutics is expanding, and the pipeline is diverse. Gain insight into how you can fast-track your molecule's development with verified synthesizers, columns, and scientific support and expertise.
-
Imagine The Future: Enhanced Oligonucleotide Synthesis
3/4/2024
Learn about flexible control software that has revolutionized the way method creation, evaluation, and process optimizations for scale-up are completed.
-
Insights Into GMP Manufacturing Of RNA-LNP Drug Products
2/29/2024
Explore key considerations for manufacturing RNA-LNP drug products surrounding process and analytical development, automation, environmental monitoring, facility design, and strategic collaborations.
-
Green Gains In Biopharma Without Closing Facilities?
2/29/2024
Going green is virtually impossible for biopharma companies with legacy systems, but going greener might be within reach. Here are some ideas to get started.
-
How Pharma 4.0 Can Unlock The Full Potential Of External Manufacturing
2/27/2024
To address today's challenges and other headwinds, pharma/biotech organizations and CMO/CDMO partners need to re-evaluate and improve externalized operating models. Consider further investing in digitalizing collaboration processes as part of operational excellence and digital transformation road map efforts.
-
Using Automated Spinoculation For CAR T Cell Lentiviral Transduction
2/26/2024
There is a growing demand for closed and automated lentiviral transduction steps in CAR T cell therapy workflows. Learn about a potential solution to address this unmet need.